St. Jude physicians demonstrate that children with bilateral Wilms tumor, a cancer of the kidneys, can retain normal function in both kidneys by undergoing a procedure called bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable.
Kay Kafe, the hospital's renovated and expanded cafeteria, opens. St. Jude purposefully has just one cafeteria for all patients, families, physicians and staff.
Peter Doherty, PhD, of Immunology is elected to the Institute of Medicine of the National Academy of Sciences.
Investigators show how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection.
Researchers discover that the drug amifostine is effective in preventing deafness in children with localized medulloblastoma.
St. Jude is designated as a National Cancer Institute Comprehensive Cancer Center, making St. Jude the first and only cancer center solely focused on pediatric cancer to receive this distinction.
The first therapeutic monoclonal antibody produced by the Children's GMP, LLC, is approved by the Food and Drug Administration for use in clinical trials. The antibody is primarily produced to treat neuroblastoma.
Researchers find evidence that a series of genetic mutations work together to cause BCR-ABL1-positive acute lymphoblastic leukemia (ALL), an aggressive and often fatal form of leukemia. The researchers also find that loss of the IKZF1 gene accompanies the transformation of chronic myeloid leukemias to a life-threatening, acute stage.